[September 25, 2017] |
|
Global Cancer Immunotherapy Markets Report 2017 - Research and Markets
The "Cancer
Immunotherapy: Building on Initial Successes to Improve Clinical
Outcomes" report has been added to Research and Markets'
offering.
As discussed in this report, researchers have found that checkpoint
inhibitors produce tumor responses by reactivating TILs (tumor
infiltrating lymphocytes)especially CD8+ cytotoxic T cells. This key
observation is perhaps the most important factor driving development of
second-wave immuno-oncology strategies. As a result, researchers have
been developing biomarkers that distinguish inflamed (i.e.,
TIL-containing) tumors - which are susceptible to checkpoint inhibitor
therapy - from cold tumors, which are not. They have also been working
to develop means to render cold tumors inflamed, via treatment with
various conventional therapies and/or development of novel agents. These
studies are the major theme of second-wave immuno-oncology, or
immuno-oncology 2.0.
Moreover, treatment of advanced melanoma (the cancer for which the
largest amount of data on immunotherapy has been amassed) with
checkpoint inhibitors has in some cases produced spectacular results.
For example, data released at the May 2016 ASCO Annual Meeting indicate
that 40% of metastatic melanoma patients who received pembrolizumab
(Merck's Keytruda) in a large clinical trial are still alive three years
later. is represents a substantial improvement over just a few years
ago, when the average survival time for patients with advanced melanoma
was measured in months. Nevertheless, metastatic melanoma remains
incurable.
Furthermore, in many studies in advanced melanoma and other cancers,
only a minority of patients have benefited from immunotherapy
treatments. Researchers and companies are therefore looking for ways to
build on the initial successes of the immuno-oncology field to improve
outcomes for more patients, hence the need for an immuno-oncology 2.0.
Agents that are intended to improve the results of treatent with agents
like checkpoint inhibitors may also be referred to as second-wave
immuno-oncology agents.
Highlights of this Report Include:
-
Approvals of checkpoint inhibitors
-
Biomarkers for checkpoint inhibitor treatments
-
Approved and clinical-stage immunotherapy biologics other than
checkpoint inhibitors
-
Immunotherapy with TIL cells
-
Commercialization of TIL therapy
-
Adoptive immunotherapy with genetically engineered T cells bearing
chimeric antigen receptors (CARs)
-
Manufacturing issues with CAR T-cell therapies
-
General conclusions on the progress of cellular immunotherapy
-
Outlook for cancer immunotherapy
What you will Learn:
-
Why is immuno-oncology important, in terms of advancing cancer
treatment beyond the traditional modalities of chemotherapy, radiation
therapy, and surgery? What is immuno-oncology 2.0, and how might it
advance the field of cancer immunotherapy?
-
What are the major classes of current and emerging immuno-oncology
therapeutics?
-
How do these agents work?
-
Which immuno-oncology drugs have been approved? Which late-stage
agents are likely to reach the market in the next 5 years? How might
these newer agents benefit patients?
-
How are researchers, physicians, and companies attempting to achieve
improved results with immuno-oncology treatments, in terms of
increasing the numbers of patients who benefit from these treatments,
achieving improved patient survival, and treating previously
untreatable and incurable types of cancer?
-
Why has there been such a high rate of failure in the field of
therapeutic anticancer vaccines? How are researchers and companies
attempting to use immuno-oncology 2.0 strategies to reduce the numbers
of failures, and thus to benefit patients?
-
Why is neoantigen science important in immuno-oncology, especially in
development of novel vaccines and cellular immunotherapies? Which
academic research groups, and established and emerging companies, are
developing neoantigen-based therapies?
-
What are the cellular immunotherapy products that are emerging in
2017? What are the issues in manufacturing cellular immunotherapy
products, and in administering them to patients safely? Why has it
been difficult to commercialize tumor infiltration lymphocyte (TIL)
therapies, despite their success in treating metastatic melanoma?
-
What is the expected market size for cancer immunotherapy in the
2017-2024 period? How might that market size be affected by the entry
of new immuno-oncology 2.0 agents, and of cellular immunotherapy
products?
Companies Mentioned
-
Aduro Biotech
-
Amgen
-
Argos Therapeutics
-
Bavarian Nordic
-
Bellicum Pharmaceuticals
-
bluebird bio
-
Celldex
-
Cellectis
-
Dendreon
-
Genelux
-
Genentech
-
Juno Therapeutics
-
Kite Pharma
-
MacroGenics
-
MedImmune
-
Nektar Therapeutics
-
Novartis
-
Regeneron
-
Roche
-
Sydys Corporation
-
TapImmune
-
Valeant
-
Xencor
For more information about this report visit https://www.researchandmarkets.com/research/zh84d4/cancer
View source version on businesswire.com: http://www.businesswire.com/news/home/20170925006135/en/
[ Back To TMCnet.com's Homepage ]
|